NCT03800173View on ClinicalTrials.gov

A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 10, 2018

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Marburg Virus Disease
Interventions
DRUG

galidesivir

galidesivir IV infusion

DRUG

placebo

placebo IV infusion

Trial Locations (1)

66219

PRA Health Sciences, Lenexa

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

BioCryst Pharmaceuticals

INDUSTRY